Discovery of Potent and Orally Bioavailable Pyrimidine Amide cGAS Inhibitors via Structure-Guided Hybridization

IF 3.5 3区医学 Q2 CHEMISTRY, MEDICINAL

ACS Medicinal Chemistry Letters Pub Date : 2024-11-24 DOI:10.1021/acsmedchemlett.4c0047110.1021/acsmedchemlett.4c00471

Patrick Cyr*, Lee D. Fader, Jason D. Burch, Kelly A. Pike, Daniel V. Sietsema, Marc-Olivier Boily, Stéphane Ciblat, Nicolas Sgarioto, Alexander M. Skeldon, Samuel Gaudreault, Philippe Le Gros, Valérie Dumais, Daniel J. J. McKay, Nathan S. Abraham, Ria Seliniotakis and Ramsay E. Beveridge*,

{"title":"Discovery of Potent and Orally Bioavailable Pyrimidine Amide cGAS Inhibitors via Structure-Guided Hybridization","authors":"Patrick Cyr*, Lee D. Fader, Jason D. Burch, Kelly A. Pike, Daniel V. Sietsema, Marc-Olivier Boily, Stéphane Ciblat, Nicolas Sgarioto, Alexander M. Skeldon, Samuel Gaudreault, Philippe Le Gros, Valérie Dumais, Daniel J. J. McKay, Nathan S. Abraham, Ria Seliniotakis and Ramsay E. Beveridge*, ","doi":"10.1021/acsmedchemlett.4c0047110.1021/acsmedchemlett.4c00471","DOIUrl":null,"url":null,"abstract":"Using a high-throughput screening (HTS) approach, a new GTP-site binding pyridine-carboxylate series of cGAS inhibitors was discovered. The biochemical potency of this new pyridine carboxylate series was improved 166-fold from the original hit to double-digit nanomolar levels using structure-based design insights, but the series was found to suffer from low permeability and low bioavailability. A structure-based hybridization of the metal-binding motifs of the pyridine carboxylate series and our previously disclosed tetrahydrocarboline GTP-site ligand 23 identified pyrimidine amide compound 36. Compound 36 is potent against both human and mouse cGAS isoforms and has a favorable pharmacokinetic (PK) profile in mice. Additionally, compound 36 displayed a dose-dependent reduction in cGAMP production in a ConA pharmacodynamic mouse model of acute liver injury, demonstrating potential utility as an in vivo tool compound for further investigation of the cGAS pathway.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"15 12","pages":"2201–2209 2201–2209"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00471","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Using a high-throughput screening (HTS) approach, a new GTP-site binding pyridine-carboxylate series of cGAS inhibitors was discovered. The biochemical potency of this new pyridine carboxylate series was improved 166-fold from the original hit to double-digit nanomolar levels using structure-based design insights, but the series was found to suffer from low permeability and low bioavailability. A structure-based hybridization of the metal-binding motifs of the pyridine carboxylate series and our previously disclosed tetrahydrocarboline GTP-site ligand 23 identified pyrimidine amide compound 36. Compound 36 is potent against both human and mouse cGAS isoforms and has a favorable pharmacokinetic (PK) profile in mice. Additionally, compound 36 displayed a dose-dependent reduction in cGAMP production in a ConA pharmacodynamic mouse model of acute liver injury, demonstrating potential utility as an in vivo tool compound for further investigation of the cGAS pathway.

Abstract Image

查看原文本刊更多论文

利用高通量筛选（HTS）方法，发现了一种新的与 GTP 位点结合的吡啶-羧酸盐系列 cGAS 抑制剂。利用基于结构的设计洞察力，这种新型吡啶羧酸盐系列的生化效力从最初的命中提高了 166 倍，达到两位数纳摩尔水平，但发现该系列存在渗透性低和生物利用率低的问题。通过对吡啶羧酸盐系列的金属结合基团和我们之前公开的四氢咔啉 GTP 位配体 23 进行基于结构的杂交，发现了嘧啶酰胺化合物 36。化合物 36 对人类和小鼠的 cGAS 异构体都有很强的抑制作用，而且在小鼠体内具有良好的药代动力学（PK）特征。此外，在急性肝损伤的 ConA 药效学小鼠模型中，化合物 36 显示出剂量依赖性的 cGAMP 生成减少效应，这表明它有可能成为进一步研究 cGAS 通路的体内工具化合物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Medicinal Chemistry Letters CHEMISTRY, MEDICINAL-

CiteScore

7.30

自引率

2.40%

发文量

328

审稿时长

1 months

期刊介绍： ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to: Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics) Biological characterization of new molecular entities in the context of drug discovery Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc. Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic Mechanistic drug metabolism and regulation of metabolic enzyme gene expression Chemistry patents relevant to the medicinal chemistry field.